Anaptysbio vs Rhythm Pharmaceuticals
Anaptysbio is the larger business, with $235m of revenue in fiscal 2025 against $190m for Rhythm Pharmaceuticals (1.2 times as much). Anaptysbio grew faster (157.0% against 45.8%). Anaptysbio kept more of each dollar of sales as profit: a net margin of -5.6% against -103.6%. Anaptysbio carries less debt relative to equity (0.0% against 77.8%).
| Latest fiscal year | AnaptysbioANAB, 2025 | Rhythm PharmaceuticalsRYTM, 2025 |
|---|---|---|
| Revenue | $235m | $190m |
| Revenue growth | 157.0% | 45.8% |
| Net income | −$13.2m | −$197m |
| Operating margin | 96.7% | -101.2% |
| Net margin | -5.6% | -103.6% |
| Return on equity | -24.5% | — |
| Free cash flow | $19.6m | −$117m |
| Cash | $138m | $54.3m |
| Total debt | $0 | $108m |
| Debt to equity | 0.0% | 77.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $68.6m | — |
| Employees | 104 | 414 |
| Market value | $1.39bn | $6.43bn |
| Price vs our value range | — | — |
| Moat score | 13 (Weak) | 25 (Weak) |
| Insider trades, 12 months | 0 buys, 42 sales | 0 buys, 50 sales |